← Back to Search

Alkalinizing Agent

Sodium Bicarbonate for Acute Kidney Injury

Phase 4
Waitlist Available
Led By Ankit Sakhuja, MD
Research Sponsored by West Virginia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days post-index hospitalization
Awards & highlights

Study Summary

This study is evaluating whether a protocol to manage urine alkalization using a simple medication may help prevent acute kidney injury in patients testing positive for COVID-19.

Eligible Conditions
  • Acute Kidney Injury
  • Coronavirus Disease
  • Coronavirus Infection
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days post-index hospitalization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days post-index hospitalization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Days Alive Free of Stage 2-3 AKI
pH
Secondary outcome measures
Hospital-Free
Stage 2-3 AKI
Vent-Free

Trial Design

2Treatment groups
Active Control
Group I: Sodium BicarbonateActive Control1 Intervention
Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
Group II: Standard of CareActive Control1 Intervention
Standard of Care treatment

Find a Location

Who is running the clinical trial?

West Virginia UniversityLead Sponsor
175 Previous Clinical Trials
56,303 Total Patients Enrolled
1 Trials studying Acute Kidney Injury
142 Patients Enrolled for Acute Kidney Injury
Ankit Sakhuja, MDPrincipal InvestigatorWest Virginia University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Kidney InternationalJournal
Renal Histopathological Analysis of 26 Postmortem Findings of Patients with COVID-19 in China
Su, Hua, Ming Yang, Cheng Wan, Li-Xia Yi, Fang Tang, Hong-Yan Zhu, Fan Yi, et al.. 2020. “Renal Histopathological Analysis of 26 Postmortem Findings of Patients with COVID-19 in China”. Kidney International. Elsevier BV. doi:10.1016/j.kint.2020.04.003.
The LancetJournal
Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study
Zhou, Fei, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, et al.. 2020. “Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30566-3.
Clinical Journal of the American Society of NephrologyJournal
Health Care Costs Associated with AKI
Collister, David, Neesh Pannu, Feng Ye, Matthew James, Brenda Hemmelgarn, Betty Chui, Braden Manns, and Scott Klarenbach. 2017. “Health Care Costs Associated with AKI”. Clinical Journal of the American Society of Nephrology. American Society of Nephrology (ASN). doi:10.2215/cjn.00950117.
JamaJournal
Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–infected Pneumonia in Wuhan, China
Wang, Dawei, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, Binbin Wang, et al.. 2020. “Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–infected Pneumonia in Wuhan, China”. Jama. American Medical Association (AMA). doi:10.1001/jama.2020.1585.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top